研究者主導研究(Investigator Sponsored Research:ISR)


10月1日より受付を開始いたします。受付終了は11月30日です。

諸般の事情により、Area of Interestの変更、臨床研究対象製品の変更、原末提供対象化合物の変更をいたしました。プログラム内容をご確認くださいますようお願い申し上げます。

プログラムのご紹介

支援方法

対象とする研究

Area of Interest

領域製品募集するテーマ
OncologyVyloy®
(Zolbetuximab)
Practice informing*:
  • HER2-ve, CLDN18.2+ LA unresectable mGC/GEJC patient sub-segments
  • Adverse event management (prevention and treatment)
  • Real-world effectiveness/safety
The following proposal types will not be considered at this time:
  • Duplicative with Zolbetuximab development studies
  • Evaluation of altered route
  • Combinations with investigational therapies
  • Low CLDN18.2 expressing (<75% of tumor cells with moderate to strong membranous staining) G/GEJ tumors
* CLDN 18.2 testing in ISR studies is recommended to be conducted with the Ventana assay.
OncologyPadcev®
(Enfortumab Vedotin) 
  • AE prevention, treatment and mitigation studies to generate evidence on strategies that inform AE management and support appropriate treatment duration and clinical outcomes
  • Characterizing EV treatment in clinically relevant UC patient subgroups with limited data
  • Studies evaluating dose modification strategies for the management of selected AEs (skin toxicity and peripheral neuropathy) in accordance with local labels
(Unapproved agents and preclinical models of resistance are currently not being considered)
The following proposal types will not be considered at this time:
  • Research for enfortumab vedotin duplicative with
    • clinical development program (CDP)
    • ongoing ISR program
    • ongoing/planned HEOR studies
  • Evaluation of altered route, dose or schedule of enfortumab vedotin that are inconsistent with approved local label
  • Exploration in tumor types outside UC
  • Combinations of enfortumab vedotin with investigational/unapproved agents, including altered route, dose, or schedule of an approved agent that are inconsistent with regional regulatory approval
  • Economic models and outputs with enfortumab vedotin
  • Preclinical models of resistance with enfortumab vedotin
  • Nectin-4 as a predictive biomarker that is duplicative with the development program
OncologyXospata®
(Gilteritinib Fumarate)

  • Combination therapies with gilteritinib in FLT3m+ AML
  • Sequencing with therapeutic options in FLT3m+ AML
  • Post-consolidation maintenance & resumption therapy in FLT3m+ AML
  • MRD and impact on treatment outcomes in gilteritinib treated AML patients
The following proposal types will not be considered at this time:
  • Pediatric studies
  • Wild type FLT3 acute myeloid leukemia (AML) or any other malignancy
  • Combination with other FLT3 inhibitors and head-to-head studies with other FLT3 inhibitors
OphthalmologyIzervay®
(Avacincaptad Pegol)
  • Structural, functional and patient-centric outcomes with ACP
  • Patient-reported outcome (PROs) and quality of life (QoL) in response to ACP treatment
  • Use of artificial intelligence (AI) to better understand ACP outcomes
  • Treatment of GA in patients with other ocular and relevant comorbidities, including the use of anti-VEGF therapy in the same or fellow eye
The following proposal types will not be considered at this time:
  • Post-Hoc analysis on current Astellas dataset, such as Gather I & II, including use of training data for AI algorithms
  • Head-to-head studies vs. other complement inhibitors or GA treatments
  • Use of ACP for the treatment of conditions/diseases other than GA

研究申請から終了までのプロセス

Process from research application to completion

留意事項

申請方法

本プログラムに関するご質問

ユーザーガイド